MX2019008413A - Celulas pluripotentes inmunodiseñadas. - Google Patents

Celulas pluripotentes inmunodiseñadas.

Info

Publication number
MX2019008413A
MX2019008413A MX2019008413A MX2019008413A MX2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A
Authority
MX
Mexico
Prior art keywords
pluripotent cells
avoid
provides
immunoengineered
rejection
Prior art date
Application number
MX2019008413A
Other languages
English (en)
Inventor
SCHREPFER Sonja
Deuse Tobias
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019008413A publication Critical patent/MX2019008413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/005—Vectors comprising a special translation-regulating system cell cycle specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención proporciona células pluripotentes que se usan terapéuticamente para regenerar tejidos que evitan el rechazo de los sujetos que las reciben. En particular, la invención proporciona células pluripotentes hipoinmunogénicas que evitan el rechazo inmune del huésped. Las células carecen de antígenos inmunes importantes que desencadenan respuestas inmunes y están diseñadas para evitar la endocitosis fagocítica. La invención proporciona además células pluripotentes "disponibles en el mercado" universalmente aceptables y derivados de las mismas para generar o regenerar tejidos y órganos específicos.
MX2019008413A 2017-01-13 2018-01-14 Celulas pluripotentes inmunodiseñadas. MX2019008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762445969P 2017-01-13 2017-01-13
PCT/US2018/013688 WO2018132783A1 (en) 2017-01-13 2018-01-14 Immunoengineered pluripotent cells

Publications (1)

Publication Number Publication Date
MX2019008413A true MX2019008413A (es) 2019-09-13

Family

ID=61148505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008413A MX2019008413A (es) 2017-01-13 2018-01-14 Celulas pluripotentes inmunodiseñadas.

Country Status (12)

Country Link
US (2) US20190376045A1 (es)
EP (1) EP3568464A1 (es)
JP (2) JP2020505025A (es)
KR (1) KR20190103373A (es)
CN (1) CN110177869A (es)
AU (1) AU2018207649A1 (es)
BR (1) BR112019014257A2 (es)
CA (1) CA3049766A1 (es)
EA (1) EA201991692A1 (es)
IL (1) IL267616A (es)
MX (1) MX2019008413A (es)
WO (1) WO2018132783A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CA3054621A1 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
BR112021000639A2 (pt) * 2018-07-17 2021-04-13 The Regents Of The University Of California Célula-tronco pluripotente induzida hipoimunogênica (hip) isolada, célula car-t hipoimune isolada, método de tratamento de um paciente com câncer por meio da administração de uma composição, população pura de células car-t hipoimunes, e método de produção de células car-t hipoimunes isoladas
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
CN113195724A (zh) * 2018-09-26 2021-07-30 新加坡国立大学 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111424016A (zh) * 2019-01-09 2020-07-17 复旦大学 降低细胞免疫原性的诱导型多能干细胞系及建立方法
JP2022526218A (ja) * 2019-02-15 2022-05-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 汎用ドナー幹細胞及び関連する方法
JP2022532174A (ja) * 2019-05-10 2022-07-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾多能性細胞
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
AU2020307550A1 (en) 2019-06-26 2022-02-03 The Regents Of The University Of California SIRPalpha-silenced natural killer (NK) cells
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
EP4022037A1 (en) 2019-07-10 2022-07-06 Helmuth Heinrich Kunz Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
CA3150233A1 (en) 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
JP2022547505A (ja) * 2019-09-05 2022-11-14 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
KR20220070456A (ko) * 2019-09-09 2022-05-31 스크라이브 테라퓨틱스 인크. 면역치료법에 사용하기 위한 조성물 및 방법
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
KR20220082045A (ko) * 2019-10-15 2022-06-16 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Fc 격리를 통한 이식된 세포 보호
EP4090743A1 (en) 2020-01-13 2022-11-23 Sana Biotechnology, Inc. Modification of blood type antigens
WO2021146627A1 (en) 2020-01-17 2021-07-22 Sana Biotechnology, Inc. Safety switches for regulation of gene expression
US20230293593A1 (en) 2020-03-25 2023-09-21 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
EP4138893A1 (en) * 2020-04-21 2023-03-01 Intima Bioscience, Inc. Cellular vaccine platform and methods of use
EP4149525A1 (en) * 2020-05-15 2023-03-22 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
KR20230074718A (ko) 2020-08-13 2023-05-31 사나 바이오테크놀로지, 인크. 저면역원성 세포로 감작된 환자를 치료하는 방법 및 관련 방법 및 조성물
CN112342196A (zh) * 2020-08-18 2021-02-09 未来智人再生医学研究院(广州)有限公司 一种免疫兼容可逆的通用型多能干细胞及其应用
JP2023546300A (ja) * 2020-10-20 2023-11-01 リプレイ ホールディングス，インク． 細胞治療のための方法および組成物
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114107211A (zh) * 2020-12-04 2022-03-01 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
EP4301380A1 (en) 2021-03-03 2024-01-10 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
EP4306634A1 (en) * 2021-03-09 2024-01-17 Riken Method for producing hypoimmunogenic retinal pigment epithelial cells
EP4313087A1 (en) * 2021-03-30 2024-02-07 The Regents of the University of California Transplanted cell protection via modified fc receptors
KR20240011184A (ko) * 2021-05-24 2024-01-25 상가모 테라퓨틱스, 인코포레이티드 Ciita 표적화 아연 핑거 뉴클레아제
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019229A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
CN117904109A (zh) * 2021-08-27 2024-04-19 浙江大学 一种超级增强子核心序列调控b2m基因表达的效果及应用
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN114958768B (zh) * 2022-06-02 2023-03-24 健颐生物科技发展(山东)有限公司 Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
CN117343962A (zh) * 2022-06-29 2024-01-05 中国科学院上海营养与健康研究所 免疫兼容型人多能干细胞、其制备方法及应用
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
WO2024012420A1 (zh) * 2022-07-11 2024-01-18 士泽生物医药（苏州）有限公司 一种表达faslg的通用型细胞及其制备方法
CN117431217A (zh) * 2022-07-12 2024-01-23 上海驯鹿生物技术有限公司 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
GB202212144D0 (en) * 2022-08-19 2022-10-05 Resolution Therapeutics Ltd Cells for therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
CN102459575A (zh) * 2009-06-05 2012-05-16 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA3085032A1 (en) * 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
CA2945393C (en) * 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
BR112017018224A2 (pt) * 2015-03-11 2018-04-17 Cellectis métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CN108368520B (zh) * 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造

Also Published As

Publication number Publication date
IL267616A (en) 2019-08-29
AU2018207649A1 (en) 2019-07-11
KR20190103373A (ko) 2019-09-04
US20230348862A1 (en) 2023-11-02
WO2018132783A1 (en) 2018-07-19
CA3049766A1 (en) 2018-07-19
BR112019014257A2 (pt) 2020-04-28
NZ754898A (en) 2023-11-24
EA201991692A1 (ru) 2019-12-30
JP2020505025A (ja) 2020-02-20
US20190376045A1 (en) 2019-12-12
JP2023052079A (ja) 2023-04-11
CN110177869A (zh) 2019-08-27
EP3568464A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
MX2021000614A (es) Células diferenciadas de células pluripotentes inmunodiseñadas.
AU2022228122B2 (en) Interleukin-21 muteins and methods of treatment
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2019005127A (es) Poblaciones y productos de células madre mesenquimales y sus usos.
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
NZ737471A (en) Hydrophilic linkers for conjugation
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MY191944A (en) Binding proteins and methods of use thereof
JOP20190134A1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12017501979A1 (en) Pharmaceutical compound
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
EA202190296A1 (ru) Клетки, дифференцированные из плюрипотентных клеток, полученных методами иммуноинженерии